Literature DB >> 28164537

FLT3 Gene Mutation Profile and Prognosis in Adult Acute Myeloid Leukemia.

Aileen Azari-Yam, Javad Tavakkoly-Bazzaz, Yousef Semnani, Elham Davoudi-Dehaghani, Robabeh Ghodssi-Ghassemabadi, Soodeh Kianfar, Ameneh Saadat, Mahboobeh Masoudifard, Marjan Yaghmaie, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Sirous Zeinali.   

Abstract

BACKGROUND: Internal tandem duplication (ITD) of FMS-related tyrosine kinase 3 (FLT3) gene, which occurs in exons 14 and 15, is one of the most prevalent somatic mutations in adult acute myeloid leukemia (AML) and has biological, prognostic, and therapeutic implications. The prognostic importance of codon 835 tyrosine kinase domain (TKD) mutation (exon 20), which occurs relatively frequently in adult AML, is often debated. We aimed to study the FLT3 gene mutation profile and prognosis in 139 adult Iranian patients with newly diagnosed AML.
METHODS: We determined the status of ITD and TKD mutations using fragment analysis and the polymerase chain reaction-restriction fragment polymorphism method, respectively. In addition, we used direct sequencing to confirm the results of TKD mutation analysis.
RESULTS: Twenty five percent of the patients had an ITD mutation. The mean size of the inserted fragment was 63.5 base pairs. Twenty percent of the ITD-positive patients showed more than one mutated population upon polymerase chain reaction. Statistical analyses showed that the ITD mutation was associated with a decreased overall survival among patients in the intermediate cytogenetic risk group (p-value = 0.013). The size of the ITD was not correlated with overall survival. Eight out of 139 patients (5.7%) had the codon 835 mutation. One new mutation of the insertion/deletion type was discovered. Analyses did not show any relationship between the TKD mutation and overall survival. Two patients (1.4%) showed concurrent TKD and ITD mutations. The TKD and ITD mutation rates of the FLT3 gene were consistent with previous studies on AML patients.
CONCLUSIONS: This study supports the results of previous studies regarding the association of the FLT3-ITD mutation and poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28164537     DOI: 10.7754/Clin.Lab.2016.160324

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  4 in total

1.  A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia.

Authors:  Yi Zhang; Bi-De Zhao; Cheng-Cheng Wang; Yun-Gui Wang; Hua-Feng Wang; Jing-Han Wang; Li-Xia Liu; Feng Lou; Shan-Bo Cao; Xiao-Xia Hu; Ai-Jie Huang; Jian-Min Yang; Hai-Tao Meng; Wen-Juan Yu; Hong-Yan Tong; Jian-Min Wang; Jie Jin
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis.

Authors:  Minglei Yang; Jian Zhao; Tielong Liu; Xinghai Yang; Haifeng Wei; Wei Xu; Jianru Xiao
Journal:  Cancer Manag Res       Date:  2018-08-14       Impact factor: 3.989

3.  Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis.

Authors:  Shuyi Chen; Yimin Chen; Zhiguo Zhu; Huo Tan; Jielun Lu; Pengfei Qin; Lihua Xu
Journal:  Int J Med Sci       Date:  2020-05-18       Impact factor: 3.738

4.  Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia.

Authors:  Sai Huang; Zhi Huang; Chao Ma; Lan Luo; Yan-Fen Li; Yong-Li Wu; Yuan Ren; Cong Feng
Journal:  Ann Transl Med       Date:  2020-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.